MedTrace Logo

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-10-19

No results posted yet for this study

Summary

Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

DRUG

Docetaxel

Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

DRUG

TroVax

Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37

Sponsors & Collaborators

  • MedSource LLC

    collaborator OTHER

  • Oxford BioMedica

    lead INDUSTRY

Principal Investigators

  • Anna C. Ferrari, MD · New York University Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01194960 on ClinicalTrials.gov